CeriBell (NASDAQ:CBLL) Issues Earnings Results

CeriBell (NASDAQ:CBLL) issued its quarterly earnings results on Monday. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13), FiscalAI reports. The business had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.

CeriBell Trading Down 0.7%

Shares of CBLL stock traded down $0.14 on Monday, reaching $20.06. The company had a trading volume of 306,852 shares, compared to its average volume of 307,145. The stock has a market cap of $759.71 million, a PE ratio of -13.65 and a beta of 0.99. The company has a 50-day moving average of $19.17 and a 200-day moving average of $18.71. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13. CeriBell has a 12 month low of $10.85 and a 12 month high of $24.33.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CeriBell in a research note on Monday, April 6th. BTIG Research reiterated a “buy” rating and set a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.20.

Insider Activity

In other CeriBell news, Director Josef Parvizi sold 16,714 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $20.27, for a total value of $338,792.78. Following the sale, the director directly owned 722,652 shares in the company, valued at approximately $14,648,156.04. This trade represents a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CTO Raymond Woo sold 11,112 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72. Following the completion of the transaction, the chief technology officer directly owned 166,912 shares of the company’s stock, valued at $3,097,886.72. This trade represents a 6.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 175,119 shares of company stock worth $3,310,772 in the last ninety days. Company insiders own 20.10% of the company’s stock.

Institutional Investors Weigh In On CeriBell

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in shares of CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after purchasing an additional 374,179 shares in the last quarter. Rhumbline Advisers raised its holdings in CeriBell by 109.9% during the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock worth $614,000 after buying an additional 17,177 shares during the period. New York State Common Retirement Fund raised its holdings in CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after buying an additional 5,200 shares during the period. Quantbot Technologies LP lifted its stake in CeriBell by 70.3% in the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after buying an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. acquired a new position in shares of CeriBell in the second quarter valued at approximately $197,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.